Markets NRXP

NRx Pharma Submits ANDA For Preservative-free IV Ketamine

June 05, 2025 — 09:03 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - NRx Pharmaceuticals, Inc. (NRXP), Thursday said it has submitted Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for preservative-free IV ketamine formulation, NRX-100, for all approved uses such as anesthesia and pain management.

NRx expects priority review from the FDA considering the current and anticipated drug shortage.

This filing supplements the New Drug Application for NRX-100 in suicidal depression with a PDUFA action date anticipated in late 2025.

The current annual ketamine market is estimated at $750 million with worldwide demand expected to increase to $3.35 billion by 2034.

The company anticipates filing a citizen's petition with the FDA to remove benzethonium chloride, a known neurotoxic and cytotoxic substance, from presentations of ketamine intended for intravenous use.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
NRXP

Latest Articles
Data is currently not available